Lonza Group AG stock (CH0013841017): earnings reset, contract wins and recovery hopes

Lonza Group AG is reshaping its business after a difficult 2023, marked by weaker guidance and the divestment of its former specialty ingredients unit. New CDMO contracts, a refocus on biopharma and recent share price swings keep the Swiss stock in focus for global and US investors.

Lonza Group AG is in the middle of a strategic reset after a volatile period for its contract development and manufacturing business, with investors watching how new biopharma projects and shifting demand for biologics and cell and gene therapies will translate into earnings and cash flow, according to company updates and recent financial reports published in 2024 and early 2025.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza Group
• Sector/industry: Life sciences, biopharmaceutical contract manufacturing (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: Global biopharma and biotech customers in Europe, North America and Asia
• Key revenue drivers: Contract development and manufacturing services for biologics, cell and gene therapies, capsules and pharmaceutical technologies
• Home exchange/listing venue: SIX Swiss Exchange (ticker: LONN)
• Trading currency: Swiss franc (CHF)

Lonza Group AG: core business model

Lonza Group AG operates as a leading contract development and manufacturing organization that helps pharmaceutical and biotechnology companies bring new therapies from early-stage development to commercial production. The group focuses on biologics, small molecules and advanced therapies, supplying capacity, process know-how and regulatory expertise on a fee-for-service basis to global drug developers.

The company’s model relies on long-term contracts and multi-year programs, often starting with process development and scaling up to clinical and commercial manufacturing. This portfolio structure means revenue visibility is tied to the timing and success rate of client pipelines, which can create periods of rapid growth when key molecules progress, as well as slower phases when projects are delayed or terminated.

In recent years, Lonza has shifted its portfolio away from lower-margin, more cyclical businesses. The separation of its former specialty ingredients activities and an increased emphasis on biologics and cell and gene therapies are intended to focus resources on areas with structurally higher demand and stronger pricing power, according to company strategy presentations and investor communications published in 2023 and 2024.

Main revenue and product drivers for Lonza Group AG

The Biologics division remains a central pillar of Lonza’s revenue and earnings, providing development, clinical and commercial manufacturing for monoclonal antibodies, complex biologics and increasingly biosimilars. Capacity utilization in large-scale mammalian facilities and the mix of higher-margin late-stage and commercial programs versus earlier-stage work are key determinants of profitability for this segment, as highlighted in financial updates and capital markets presentations released in 2024.

Another important driver is the Cell & Gene segment, where Lonza offers development and manufacturing services for cell therapies, gene therapies and viral vectors. While this business is still smaller than the biologics platform, it is viewed internally as a strategic growth area, as the industry continues to bring more advanced therapies into clinical development. Demand in this area can be uneven, reflecting evolving regulatory pathways and the funding environment for smaller biotech companies.

The Capsules & Health Ingredients and Small Molecules activities add diversification by providing oral dosage forms, capsules and chemical manufacturing capabilities. These segments tend to be less volatile than some emerging therapy platforms but can be more exposed to general pharmaceutical market dynamics and competition. The balance between these units helps smooth overall group revenue, although margin profiles differ substantially across the portfolio.

Industry trends and competitive position

Lonza competes in a global CDMO market that has expanded alongside the shift from small-molecule blockbusters to complex biologics and specialty therapies. Pharmaceutical and biotech clients often prefer to outsource development and production of sophisticated modalities to specialized partners, rather than investing heavily in their own manufacturing infrastructure, a trend that has supported long-term growth for the CDMO industry.

Within this landscape, Lonza is positioned among the larger players, with manufacturing sites in Europe, North America and Asia and a broad portfolio that spans early-stage development through to commercial production. This scale can be an advantage when clients seek integrated solutions across multiple therapies and regions, but it also requires significant capital expenditure and careful capacity planning to avoid underutilization.

Competitive intensity is rising as peers invest in new capacity for biologics and cell and gene therapies. Some CDMOs focus tightly on specific niches, while others, like Lonza, offer a wider range of platforms. The ability to maintain high regulatory standards, deliver complex projects on time and manage technology transfers efficiently is critical to winning and retaining contracts, especially with large pharmaceutical customers that prioritize reliability and global reach.

Why Lonza Group AG matters for US investors

For US investors looking at global healthcare exposure, Lonza offers indirect participation in a wide range of biopharma pipelines without concentrating on a single drug or company. Many of its clients are based in the United States, and a significant portion of its revenues is linked to US and global demand for biologics and advanced therapies, according to management commentary in investor presentations and earnings materials published in 2024.

Because Lonza’s shares trade primarily on the SIX Swiss Exchange in Swiss francs, US investors typically access the stock via international brokerage accounts or over-the-counter instruments. Currency fluctuations between the US dollar and the Swiss franc can influence returns when translated back into dollars, adding a layer of foreign exchange risk alongside the operational and sector-specific factors that affect the company’s performance.

Risks and open questions

Lonza’s earnings trajectory depends heavily on how client projects progress through clinical phases and into commercial production. Cancellations, delays or lower-than-expected uptake for key therapies can reduce capacity utilization, pressuring margins and cash flow. At the same time, building and validating new facilities requires substantial up-front investment, which can weigh on returns if demand does not ramp as expected.

Another area of uncertainty lies in the competitive landscape and pricing dynamics across the CDMO industry. As more players add biologics and cell and gene therapy capabilities, contract terms and margins can come under pressure, especially in areas where capacity becomes less scarce. Regulatory changes and evolving quality expectations may also necessitate additional investment to maintain compliance across multiple sites and jurisdictions.

Conclusion

Lonza Group AG occupies a central position in the global contract development and manufacturing market, offering exposure to a broad spectrum of pharmaceutical and biotech innovation. The company’s focus on biologics, cell and gene therapies and advanced pharmaceutical technologies aims to capture structural growth trends, but the path is not linear and depends on clients’ pipelines and capital allocation decisions. For US-focused portfolios, the stock represents a way to participate in international life sciences manufacturing with the added considerations of foreign exchange, regulatory complexity and industry competition.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.